152 related articles for article (PubMed ID: 10432950)
21. [Thrombopenia increased by heparin and danaparoid].
Godet G; Bertrand M; Van de Steen E; Boccara G; Koskas F
Ann Fr Anesth Reanim; 2001 Jan; 20(1):50-3. PubMed ID: 11234580
[TBL] [Abstract][Full Text] [Related]
22. Management of patients with heparin-induced thrombocytopenia: focus on recombinant hirudin.
Lubenow N; Greinacher A
J Thromb Thrombolysis; 2000 Nov; 10 Suppl 1():47-57. PubMed ID: 11155194
[No Abstract] [Full Text] [Related]
23. A comparative review of the adverse effect profiles of heparins and heparinoids.
Borris LC; Lassen MR
Drug Saf; 1995 Jan; 12(1):26-31. PubMed ID: 7537967
[TBL] [Abstract][Full Text] [Related]
24. Delayed-type hypersensitivity to subcutaneous heparin with tolerance of i.v. administration.
Liew G; Campbell C; Thursby P
ANZ J Surg; 2004 Nov; 74(11):1020-1. PubMed ID: 15550103
[No Abstract] [Full Text] [Related]
25. Fatal danaparoid-sodium induced thrombocytopenia and arterial thromboses.
Tardy B; Tardy-Poncet B; Viallon A; Piot M; Mazet E
Thromb Haemost; 1998 Sep; 80(3):530. PubMed ID: 9759647
[No Abstract] [Full Text] [Related]
26. Danaparoid sodium (Orgaran) in four children with heparin-induced thrombocytopenia type II.
Zöhrer' B; Zenz W; Rettenbacher A; Covi P; Kurnik K; Kroll H; Grubbauer HM; Muntean W
Acta Paediatr; 2001 Jul; 90(7):765-71. PubMed ID: 11519979
[TBL] [Abstract][Full Text] [Related]
27. [Clinical experience with Danaparoid-sodium: measures to be taken in heparin-induced thrombocytopenia].
Chirurg; 1998 Nov; 69(11 Suppl Massnahme):1-4. PubMed ID: 9853175
[No Abstract] [Full Text] [Related]
28. Anticoagulation in patients with heparin-induced thrombocytopenia type II.
Harenberg J; Huhle G; Piazolo L; Wang LU; Heene DL
Semin Thromb Hemost; 1997; 23(2):189-96. PubMed ID: 9200346
[TBL] [Abstract][Full Text] [Related]
29. Argatroban, a new treatment option for heparin-induced thrombocytopenia.
Cleveland KW
Crit Care Nurse; 2003 Dec; 23(6):61-6. PubMed ID: 14692173
[No Abstract] [Full Text] [Related]
30. The use of danaparoid to manage coagulopathy in a neurosurgical patient with heparin-induced thrombocytopenia type II and intracerebral haemorrhage.
Hertle DN; Hähnel S; Richter GM; Unterberg A; Sakowitz OW; Kiening KL
Br J Neurosurg; 2011 Feb; 25(1):117-9. PubMed ID: 20707682
[TBL] [Abstract][Full Text] [Related]
31. Aprotinin and organon 10172: a successful combination for coronary artery bypass surgery complicated by heparin-induced thrombocytopenia.
Alvarez MJ; Mezzatesta PJ
Aust N Z J Surg; 2000 Nov; 70(11):819-21. PubMed ID: 11147447
[No Abstract] [Full Text] [Related]
32. Successful use of danaparoid in two pregnant women with heart valve prosthesis and heparin-induced thrombocytopenia Type II (HIT).
Gerhardt A; Scharf RE; Zotz RB
Clin Appl Thromb Hemost; 2009; 15(4):461-4. PubMed ID: 18840630
[TBL] [Abstract][Full Text] [Related]
33. Eczematous plaques related to unfractionated and low-molecular-weight heparins: cross-reaction with danaparoid but not with desirudin.
Martin L; Machet L; Gironet N; Pouplard C; Gruel Y; Vaillant L
Contact Dermatitis; 2000 May; 42(5):295-6. PubMed ID: 10789857
[No Abstract] [Full Text] [Related]
34. Thromboembolic prophylaxis with danaparoïd (Orgaran) in a high-thrombosis-risk pregnant woman with a history of heparin-induced thrombocytopenia (HIT) and Widal's disease.
Macchi L; Sarfati R; Guicheteau M; Chamlian V; Pourrat O; Gruel Y; Magnin G; Brizard A; Boinot C
Clin Appl Thromb Hemost; 2000 Oct; 6(4):187-9. PubMed ID: 11030522
[TBL] [Abstract][Full Text] [Related]
35. Danaparoid sodium.
Acostamadiedo JM; Iyer UG; Owen J
Expert Opin Pharmacother; 2000 May; 1(4):803-14. PubMed ID: 11249517
[TBL] [Abstract][Full Text] [Related]
36. Tolerance of fondaparinux in a patient allergic to heparins and other glycosaminoglycans.
Ludwig RJ; Beier C; Lindhoff-Last E; Kaufmann R; Boehncke WH
Contact Dermatitis; 2003 Sep; 49(3):158-9. PubMed ID: 14678213
[No Abstract] [Full Text] [Related]
37. Parenteral anticoagulants: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.
Garcia DA; Baglin TP; Weitz JI; Samama MM
Chest; 2012 Feb; 141(2 Suppl):e24S-e43S. PubMed ID: 22315264
[TBL] [Abstract][Full Text] [Related]
38. A comparison of danaparoid and lepirudin in heparin-induced thrombocytopenia.
Farner B; Eichler P; Kroll H; Greinacher A
Thromb Haemost; 2001 Jun; 85(6):950-7. PubMed ID: 11434701
[TBL] [Abstract][Full Text] [Related]
39. Treatment of heparin-induced thrombocytopenia.
Peters FP
J Thorac Cardiovasc Surg; 1997 Sep; 114(3):517-8. PubMed ID: 9305220
[No Abstract] [Full Text] [Related]
40. Treatment of heparin-induced thrombocytopenia in cardiovascular patients.
Matthai WH
Expert Opin Pharmacother; 2006 Feb; 7(3):267-76. PubMed ID: 16448321
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
